secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-10-13T12:25:13+00:00
Accession:  0001420720-26-000030
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

iBio's IBIO-610 plus semaglutide cut lean-mass share of NHP weight loss to 6% vs 22%
--------------------------------------------------------------------------------

- In an 8-week obese NHP study (n=6 per group), fat was 93% of weight lost with single-dose IBIO-610 plus twice-weekly semaglutide, vs 77% with semaglutide alone.
- Lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone.
- IBIO-610 produced 97% reduction in active Activin E serum levels at week 8 after a single IV dose; NHP half-life was 33.2 days, potentially supporting twice-yearly human dosing.
- Data presented in an oral session at the EASD Annual Meeting on Oct. 1, 2026; iBio plans to start first-in-human trials of IBIO-610 in the first half of 2027.
- CEO/CSO Martin Brenner framed IBIO-610 as addressing the quality-of-weight-loss gap left by GLP-1 therapies; all results are preclinical.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/0001420720-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/ibio-20261013x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer